Clinical Trial

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia deserves study.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-09-12; most recent amendment 2026-03-21.
Status change: Not Yet Recruiting → Recruiting 2021-11-02
Trial Details
NCT Number NCT05052853
Lead Sponsor China Medical University Hospital
Conditions Prodromal Schizophrenia
Enrollment 48 participants
Start Date 2021-11-01
Primary Completion 2026-10 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-24